Published in Hospital and Nursing Home Week, October 28th, 2004
AMG 162, at all doses, also increased total hip BMD, similar to or greater than that resulting from Fosamax (alendronate; Merck) treatment in the same time frame.
The 1-year results of the ongoing multicenter, Phase II dose-ranging trial in healthy postmenopausal women with low BMD were presented at the American Society for Bone and Mineral Research 26th Annual Meeting in Seattle. The double-blind...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.